NEURALTIDE
Develop and commercialize a Low-Risk Medical Device to Treat Acute Ischemic Stroke
- Stage Prototype Ready
- Industry Medical Devices and Equipment
- Location Paris, France
- Currency EUR
- Founded October 2017
- Employees 3
- Incorporation Type C-corp
- Website http:// neuraltide.co
Company Summary
Neuraltide is developing a causal treatment of ischemic stroke under the form of a non-invasive Low-Risk Medical Device (MD).
This new MD is able to reduce stroke handicap by enhancing cerebral perfusion.
Our MD is a new therapeutic option for physicians and stroke patients known to have high unmet medical needs.
In Europe, 450 000 patients/year are eligible for our MD. Recurrent sales to hospitals, turn over of 11M€ expected in 2025.
Team
-
Co-founder, CEONeurologist with a rare double expertise: MD with over 10 years hospital experience including a position as Head of Neurology at Lariboisière’s Hospital in Paris and 13 years of corporate experience with Pfizer, where medical expertise was brought to the clinical development and launch of new drugs in France and Europe
-
Associate DirectorPharmacist. 25 years of experience in the industry, having been in management positions across multiple corporations including Pfizer, Boehringer Ingelheim. She has set up and managed various projects to launch new treatments in various therapeutic including stroke. She has also worked with and founded entrepreneurial ventures in the bio pharmaceutical and cosmetics industries.
-
Archange NigarCTOEngineer specialized in electronics who will guide the device through its technical development and the regulatory certification process.
-
Co-founderMD, PhD, Associate Professor, Head of Anaesthesiologic department. She brings strong expertise in medical research.
-
Quality ManagementSafety and Compliance Manager. She has worked as Project Manager in several industries, mostly in Pharmaceutical
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.